CCG-1423 | 9434

CCG-1423 is a specific inhibitor of Rho pathway-mediated signaling and activation of serum response factor (SRF) transcription. CCG-1423 displays activity in several in vitro cancer cell functional assays. CCG-1423 potently (<1 mumol/L) inhibits lysophosphatidic acid-induced DNA synthesis in PC-3 prostate cancer cells, and whereas it inhibits the growth of RhoC-overexpressing melanoma lines at nanomolar concentrations, it is less active on related lines that express lower levels of Rho. Similarly, CCG-1423 selectively stimulates apoptosis of the metastasis-prone, RhoC-overexpressing melanoma cell line (A375M2) compared with the parental cell line (A375).

CCG-1423 is a specific inhibitor of Rho pathway-mediated signaling and activation of serum response factor (SRF) transcription. CCG-1423 displays activity in several in vitro cancer cell functional assays. CCG-1423 potently (<1 mumol/L) inhibits lysophosphatidic acid-induced DNA synthesis in PC-3 prostate cancer cells, and whereas it inhibits the growth of RhoC-overexpressing melanoma lines at nanomolar concentrations, it is less active on related lines that express lower levels of Rho.

9434 | CCG-1423 DataSheet

Alternate Name/Synonyms: N-[2-[(4-Chlorophenyl)amino]-1-methyl-2-oxoethoxy]-3,5-bis(trifluoromethyl)benzamide

Appearance: White solid

Formulation: N/A

CAS Number: 285986-88-1

Structure Available?: Yes

Peptide sequence: N/A

Salt Form: No

Molecular Formula: C₁₈H₁₃ClF₆N₂O₃

Molecular Weight: 454.75

Cell-Permeable?: Yes

Purity: ≥98% by HPLC

Solubilities: DMSO (~40 mg/ml)

Handling: Protect from air and light

Country of Origin: USA

Tag Line: A Rho/serum response factor (SRF) transcription.

MDL Number: N/A

PubChem CID: 2726015

SMILES: CC(C(=O)NC1=CC=C(C=C1)Cl)ONC(=O)C2=CC(=CC(=C2)C(F)(F)F)C(F)(F)F

InChi: InChI=1S/C18H13ClF6N2O3/c1-9(15(28)26-14-4-2-13(19)3-5-14)30-27-16(29)10-6-11(17(20,21)22)8-12(7-10)18(23,24)25/h2-9H,1H3,(H,26,28)(H,27,29)

InChi Key: DSMXVSGJIDFLKP-UHFFFAOYSA-N